Back to Search
Start Over
Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia.
- Source :
- Leukemia & Lymphoma; Jan2002, Vol. 43 Issue 1, p149, 3p, 2 Charts, 1 Graph
- Publication Year :
- 2002
-
Abstract
- Examines the efficacy of rituximab, amonoclonal anti-cd20 antibody in the treatment of patients with relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Correlation between CD20 expression and the efficacy of rituximab treatment; Detection of disease progression; Determination of malignant lymphocytes in peripheral blood.
- Subjects :
- LEUKEMIA treatment
RITUXIMAB
LYMPHOCYTES
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 43
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 7104795
- Full Text :
- https://doi.org/10.1080/10428190210178